Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

被引:89
作者
Molad, Y
Gorshtein, A
Wysenbeek, AJ
Guedj, D
Majadla, R
Weinberger, A
Amit-Vazina, M
机构
[1] Rabin Med Ctr, Rheumatol Unit, IL-49100 Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Assaf Harofeh Hosp, Rheumatol Serv, IL-69978 Tel Aviv, Israel
关键词
damage; lupus; activity; hydroxychloroquine; antimalarial therapy;
D O I
10.1191/0961203302lu203ra
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus-associated irreversible organ/system damage was previously associated with various clinical and demographic features. We analysed the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) in a cohort of 151 Israeli patients followed for a mean (+/- s.d.) period of 45.7 +/- 37.4 months. Mean score of SLICC/ACR DI at the first and last encounters were 0.17 +/- 64 and 1.64 +/- 2.1. respectively (P < 0.0001). Multiple logistic regression analyses disclosed a statistically significant positive correlation with corticosteroid and cyclophosphamide therapy. Hydroxychloroquine therapy was significantly associated, with lower SLICC/ACR DI. Although the size of our study group did not allow us to find specific organs/systems which were associated with the protective effect of hydroxychloroquine, we suggest this is due to the antiatherogenic effects attributed to antimalarial therapy in SLE.
引用
收藏
页码:356 / 361
页数:6
相关论文
共 50 条
[1]   Malignancy in systemic lupus erythematosus [J].
AbuShakra, M ;
Gladman, DD ;
Urowitz, MB .
ARTHRITIS AND RHEUMATISM, 1996, 39 (06) :1050-1054
[2]  
AbuShakra M, 1997, CLIN EXP RHEUMATOL, V15, P181
[3]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[4]  
Bruce IN, 1998, CLIN EXP RHEUMATOL, V16, P435
[5]  
ESDAILE J, 1991, NEW ENGL J MED, V324, P150
[6]   Impact of disease activity and cumulative damage on the health of lupus patients [J].
Fortin, PR ;
Abrahamowicz, M ;
Neville, C ;
du Berger, R ;
Fraenkel, L ;
Clarke, AE ;
Danoff, D .
LUPUS, 1998, 7 (02) :101-107
[7]  
Gilboe IM, 2001, J RHEUMATOL, V28, P266
[8]   The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology Damage Index for Systemic Lupus Erythematosus [J].
Gladman, D ;
Ginzler, E ;
Goldsmith, C ;
Fortin, P ;
Liang, M ;
Urowitz, M ;
Bacon, P ;
Bombardieri, S ;
Hanly, J ;
Hay, E ;
Isenberg, D ;
Jones, J ;
Kalunian, K ;
Maddison, P ;
Nived, O ;
Petri, M ;
Richter, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G ;
Symmons, D ;
Zoma, A .
ARTHRITIS AND RHEUMATISM, 1996, 39 (03) :363-369
[9]   The reliability of the systemic Lupus International Collaborating Clinics American College of Rheumatology Damage Index in patients with Systemic Lupus Erythematosus [J].
Gladman, DD ;
Urowitz, MB ;
Goldsmith, CH ;
Fortin, P ;
Ginzler, E ;
Gordon, C ;
Hanly, JG ;
Isenberg, DA ;
Kalunian, K ;
Nived, O ;
Petri, M ;
SanchezGuerrero, J ;
Snaith, M ;
Sturfelt, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (05) :809-813
[10]  
Gladman DD, 1996, CLIN EXP RHEUMATOL, V14, P305